Woodford Woes Drag On For Immunocore

Unrealistic Valuations Holding Private Firms Back

Once seen as the champion of biotech start-ups, Woodford’s blind faith has shackled firms to unrealistic valuations.

Oxford
Oxford, home to T-cell receptor immunotherapy company Immunocore

The demise of Neil Woodford’s investment empire is continuing to drag on the UK biotech sector, with news that the sell off of shares in privately held life sciences companies has fallen flat.

Woodford was for many years a champion of the UK biotech sector, but a series of missteps saw the value...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip